Medtronic SPYRAL HTN-ON MED study DSMB recommends trial continuation; full cohort follow-up expected H2 2022

Medtronic plc

DSMB prespecified interim analysis recommends ON MED clinical trial enrollment continue until full sample size of 260 patients is reached.
Full cohort follow-up expected in H2 2022; trial powered to detect statistically significant therapeutic benefit at final analysis.
Medtronic reiterates FY2022 revenue and EPS guidance; long-range plan of 5%+ organic revenue growth and 8%+ adjusted EPS growth unchanged.
Company projects global renal denervation market exceeding $500M by 2026 and $2-3B by 2030.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.